KIT and acute myeloid leukemia: In the present study, 14 days of KIT inhibitors (majority receiving dasatinib) along with induction chemotherapy produced significantly superior remission rates among 21 patients with CBF‐AML compared to patients who did not receive KIT inhibitors during induction (95% vs. 83%, p = 0.01).